Kidney Disease

For commercial insurers and Medicare, it may be cost-effective to add empagliflozin to the standard of care treatment for patients with diabetic kidney disease, according to data published in the American Journal of Kidney Diseases.

In addition to the everyday burden of chronic kidney disease, patients and their caregivers report that limited opportunities and the power imbalance between them and researchers create obstacles to meaningful involvement in research.

The number of adult cancer survivors in the United States with comorbid illnesses and multiple chronic conditions has increased considerably since 2002, according to study results published in Cancer.

Kidney Disease: Improving Global Outcomes has launched two implementation tools based on a 2020 clinical practice guideline for the management of diabetes in chronic kidney disease, according to a press release from the foundation.

Regardless of baseline eGFR, non-albuminuric diabetic kidney disease correlated with increased risks of hospitalization for heart failure and chronic kidney disease progression.

Vantage Health announced its partnership with Fresenius Medical North America and a new care agreement aimed at improving outcomes for patients with late-stage chronic kidney disease, according to a company press release.

CVD leads to approximately 40% to 50% of deaths in patients with advanced chronic kidney disease or end-stage renal disease, so CV risk assessment of recipients and donors is an important part of the kidney transplantation process.

Dietitians who provide nutrition care to kidney patients are limited around the globe and availability varies in countries, according to data published in Clinical Journal of the American Society of Nephrology.

Diabetic kidney disease is the leading cause of end-stage renal disease in the U.S., and 50% of adults initiating renal replacement therapy have diabetes, according to the CDC.

One of the first studies I was involved with when I started in diabetes and kidney disease was looking at the predictors of a good outcome when you start therapy. What we use as endpoints in trials is stopping of creatinine decline and end-stage kidney disease. It takes a while to reach these endpoints. It would be ideal, before a patient is at that late stage of disease, to have an indication of whether you are on the right track.